Form 4: Cabaletta Bio General Counsel Granted Stock Options

Cabaletta Bio's General Counsel, Michael Gerard, was granted 175,000 stock options with an exercise price of $3.30 per share.

Summary

• Michael Gerard, General Counsel of Cabaletta Bio, Inc. (CABA), was granted 175,000 stock options.
• The transaction date for this grant was March 2, 2026.
• The exercise price for these stock options is $3.30 per share.
• The options have an expiration date of March 1, 2036.
• Vesting for these options begins on March 1, 2027, when 25% of the shares will vest and become exercisable.
• The remaining options will vest in twelve substantially equal quarterly installments thereafter, contingent on Mr. Gerard's continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating continued executive commitment and aligning management's interests with long-term shareholder value through equity incentives.

Positives

• The grant of stock options aligns the General Counsel's financial interests with the long-term performance and shareholder value of Cabaletta Bio.
• Equity compensation is a standard practice for retaining key executives and incentivizing their continued service and dedication to the company's success.

Future Outlook

The multi-year vesting schedule for the stock options suggests a long-term commitment from the General Counsel to Cabaletta Bio, aligning executive incentives with future company growth and performance.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options, are a prevalent and effective form of executive compensation within the biotechnology industry. This practice is designed to attract, retain, and motivate key personnel by directly linking their financial success to the company's long-term share price performance, a common strategy among growth-oriented biotech firms.

Comparison to Industry Standards

• StockSavvy.ai notes that a 10-year option term and a multi-year vesting schedule (e.g., 25% after one year, then quarterly over three years) are standard for executive equity grants in the biotechnology sector, comparable to practices observed at companies like Moderna, BioNTech, or Regeneron for their key personnel.
• The grant of 175,000 options to a General Counsel is within the typical range for a company of Cabaletta Bio's size and stage, reflecting competitive compensation practices for senior legal roles in the life sciences industry.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance.
• Employees (specifically Michael Gerard): Direct financial benefit through equity compensation, contingent on company performance and continued service.

Next Steps

• Continued vesting of the granted stock options, subject to Michael Gerard's ongoing service to Cabaletta Bio.

Key Dates

Recommendation

The grant of stock options to a key executive like the General Counsel indicates continued commitment and aligns their interests with long-term company performance. While not a direct indicator of immediate financial results, it's a standard practice for executive retention and motivation, supporting a 'hold' recommendation for existing investors.

Keywords

Cabaletta Bio, CABA, Stock Option, Insider Transaction, Form 4, Equity Grant, Executive Compensation, Michael Gerard, General Counsel